Press releases

29 February, 2016

Regulatory

Notice of extraordinary general meeting in NeuroVive Pharmaceutical AB (publ)

The shareholders in NeuroVive Pharmaceutical AB (publ) reg. no. 556595-6538 (the "Company") are hereby convened to the extraordinary general meeting, held at 10.00 a.m. on Thursday, 31 March 2016 at ...

29 February, 2016

Regulatory

NeuroVive resolves on rights issue totaling approximately SEK 94.4 million for continued development of the project portfolio

On 28 February 2016, The Board of Directors of NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or "the Company") decided to carry out a new issue of shares and warrants (units) with preferential right ...

29 February, 2016

Regulatory

NeuroVive Pharmaceutical AB (publ) – amendment number of shares and votes

Pursuant to chapter 4, § 9 of the Swedish Financial Instruments Trading Act (1991:980), the company is hereby reporting that as a result of share issue in kind conducted by NeuroVive Pharmaceutical AB ...

23 February, 2016

Regulatory

Board Selects New CEO Erik Kinnman to Lead NeuroVive

NeuroVive Pharmaceutical AB (publ) board of directors is pleased to announce that it has selected Erik Kinnman as NeuroVive's Chief Executive Officer (CEO). Erik Kinnman will assume the new role on th ...

19 February, 2016

Regulatory

NeuroVive: Year-End Report 1 Jan. 2015 – 31 Dec. 2015

Fourth Quarter (1 Oct. 2015 - 31 Dec. 2015) · Net revenues were SEK 0 (0) and other operating income was SEK 23,000 (8,000). · Loss before tax was SEK -7,366,000 (-17,346,000). · Earnings per share* w ...

14 January, 2016

Regulatory

NeuroVive buys stake in Isomerase Therapeutics

Lund, Sweden, 14 January 2016 - NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces the partial acquisition of British company Isomerase Therapeutics ("Isomerase") with t ...

13 January, 2016

Regulatory

NeuroVive enters strategic collaboration with University of Pennsylvania

Lund, Sweden, 12 January 2016 - NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that it has entered into a research partnership with University of Pennsylvania to enh ...

19 November, 2015

Regulatory

NeuroVive reports favourable safety evaluation in Phase II acute kidney injury study

Lund, Sweden, 19 November 2015 - NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that the independent safety committee has endorsed the continuation of the on-going P ...

18 November, 2015

Regulatory

NeuroVive: Interim Report 1 Jan. 2015 to 30 Sep. 2015

Focus forward on R&D

2 November, 2015

Regulatory

NeuroVive Presents Findings Targeting Complex I Deficiency at World Mitochondria Congress

Lund, Sweden, 2 November 2015 - NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces the presentation of preclinical data from its Complex I deficiency discovery program a ...

28 October, 2015

Regulatory

NeuroVive Aims to Find Path Forward in Antiviral Development Following Discontinuation of OCB-030 Preclinical Program by Arbutus

Lund, Sweden, 28 October 2015- NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that they will seek to find a suitable path forward to continue the development of the ...

23 October, 2015

Regulatory

NeuroVive Strengthens Clinical Development Team With Appointment of Dr. Magnus Hansson as Chief Medical Officer

Lund, Sweden, 23 October 2015 - NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that Dr. Magnus Hansson will be appointed as Chief Medical Officer, effective as of 1 ...